A prospective study of 123I-labeled monoclonal antibody imaging in ovarian cancer.
Thirty patients presenting with a pelvic mass were entered into a prospective study on the use of radioimmunoscintigraphy with the 123I-labeled monoclonal antibody HMFG2. The imaging data was obtained without knowledge of the clinical data and compared with subsequent surgical findings. A false-positive diagnosis of ovarian cancer was made in five of ten patients subsequently shown not to have ovarian cancer; thus the technique cannot be used as a screening test. A true-positive diagnosis was made in 19 out of 20 patients shown subsequently to have ovarian cancer. In 18 of these patients the distribution of uptake closely fitted the surgical findings. Methods of improving these results are described. In conclusion, radioimmunoscintigraphy is of no use in determining whether a pelvic mass is due to ovarian cancer, but has benefit in the evaluation of chemotherapy and may, in the future, prevent the need for second-look operations in some circumstances.
M
M
Granowska
K E
KE
Britton
J H
JH
Shepherd
C C
CC
Nimmon
S
S
Mather
B
B
Ward
R J
RJ
Osborne
M L
ML
Slevin
D000911:Antibodies, Monoclonal; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008565:Membrane Proteins; D008722:Methods; D018396:Mucin-1; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D011446:Prospective Studies; D011877:Radionuclide Imaging; D012086:Reoperation; D013997:Time Factors
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D008565:Membrane Proteins; D018396:Mucin-1